Semax
No controlled trials for focus or memory in healthy people.
A nasal peptide developed in Russia, where it is registered for stroke and other brain conditions. Outside Russia it is sold as a focus and memory booster. Nearly all the human research is Russian and falls short of modern trial standards. Also called ACTH 4-10 analog.
What the evidence shows
Side effects and risks
Who should avoid it: Treat it as untested outside its approved uses in Russia.
How it works
- Where it acts
- The exact target is unclear. It is thought to raise BDNF, a brain growth factor, and to act on melanocortin receptors.
- What it changes
- In animals, more BDNF and better survival of nerve cells after stroke.
- What people notice
- Users report sharper focus. The evidence is mostly from Russian studies.
How it has been given in studies
As nose drops. Stroke studies used a 1% solution for 5 to 21 days. Recovery studies used a 0.1% or a 1% solution.
Getting it in the United States
The legal route for Semax
Not FDA-approved. FDA advisers have reviewed, or are due to review, whether pharmacies may compound it. Until FDA acts, there is no lawful route. Vials sold for research use are unapproved drugs when marketed for people.
Routes people use for any peptide in the United States
Telehealth prescribing
Online clinics prescribe after a questionnaire, sometimes with no live doctor visit, and mail the drug. FDA moved in February 2026 to restrict mass-marketed compounded copies and claims that they are generic equivalents.
Risk: Thin medical screening. Compounded versions are not reviewed by FDA for quality.
Covers: Approved GLP-1 drugs, compounded semaglutide and tirzepatide
Source: GZERO Media, Apr 2026
Clinical trial enrolment
The only lawful way to get an unapproved peptide drug with medical monitoring. ClinicalTrials.gov lists eligibility, sites and phone numbers. Researchers note recruitment is hard when people can buy the drug on the gray market instead of risking placebo.
Risk: Possible placebo assignment, strict eligibility and travel to a study site.
Covers: Investigational peptide drugs still in development
Source: NIH, finding a clinical trial
Compounding pharmacy with prescription
Compounding was restricted from 2023. A 2026 advisory vote backed Semax, but FDA must still adopt it and rulemaking could take 12 to 24 months. Compounded versions would remain unapproved drugs.
Source: AJMC, 2026-08
Online nasal sprays and vials
An anti-doping testing body says Semax is sold online as nasal sprays or research vials. It cites analyses finding mislabeling, concentration errors or contamination in about 30 percent of grey-market peptide samples.
Source: BSCG blog, 2026-08
Routes people use for any peptide in the United States
Compounding pharmacy with prescription
A clinician prescribes and a pharmacy compounds. Twelve peptides left the FDA do-not-compound category in April 2026 and a panel backed six in July, but they are not yet formally eligible. Pharmaceutical-grade ingredient is scarce.
Risk: Legal status is unsettled until FDA rulemaking ends. Pharmacies may use research-grade ingredient.
Covers: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and similar
Source: Frier Levitt, Apr 2026
Med spas and weight-loss clinics
Very common. Secret shoppers called 75 clinics and med spas in two states after shortages ended. 92 percent offered compounded semaglutide and 87 percent tirzepatide, often mixed with B vitamins to look custom.
Risk: Four of 23 suppliers lacked sterile compounding licenses and four had disciplinary records.
Covers: Compounded semaglutide and tirzepatide
Source: American Med Spa Association on JAMA Health Forum study, Jul 2026
Concierge and longevity doctors
Cash-pay physicians build peptide plans for wealthy clients. Reporting from San Francisco says some source from overseas channels, domestic research-use-only sellers or the few compounding pharmacies that will supply clinicians.
Risk: A doctor's involvement does not guarantee a pharmaceutical-grade product.
Covers: BPC-157, thymosin alpha-1, Selank, Semax, CJC-1295, ipamorelin, retatrutide
Source: San Francisco Standard, Sep 2025
Cross-border purchase or import
FDA says importing drugs for personal use is illegal in most cases but it may not object to small personal quantities in limited situations. Reporting also describes people travelling to Mexico for injections.
Risk: Packages can be seized. Product origin and cold-chain handling are hard to check.
Covers: Approved prescription peptides sold abroad
Source: FDA, personal importation
Routes people use for any peptide in the United States
Research-chemical websites
Sites sell vials marked for research or not for human consumption, with no prescription. FDA says some ship direct to consumers with dosing directions, and it has sent warning letters. Retatrutide exists only through this route or trials.
Risk: Unknown identity, strength and sterility. No pharmacist or prescriber involved.
Covers: Retatrutide, semaglutide, tirzepatide, BPC-157 and most unapproved peptides
Source: FDA, unapproved GLP-1 drugs page
Direct orders from Chinese factories
Buyers message factory sales agents and pay by crypto or payment app. A minimum order of about ten vials pushes people to buy in bulk and share. A blockchain analysis found US buyers were the largest source of funds.
Risk: Many of the same vendors list fentanyl precursors. Lab reports sent by sellers cannot be verified.
Covers: GLP-1 copies, melanotan II, BPC-157, TB-500, GHK-Cu, epitalon
Source: TRM Labs, Oct 2026
Chat groups and social sellers
Dealers are found through Telegram, WhatsApp, Discord and influencer discount codes. In a May 2026 survey of 1,000 US users, 14.5 percent bought this way and three quarters asked an AI chatbot for dosing.
Risk: 45 percent of social media buyers in that survey reported an emergency or urgent care visit for a reaction.
Covers: Retatrutide and other research-use-only peptides
Source: The Ethos, May 2026
This describes what people do. It is not advice. The decision is yours.
What users report
Recurring themes in public forum posts, unverified and with no comparison group.
Reported benefits
- Sharper focus for a few hours
Reported problems
- Irritability or anxiety
- Nose irritation
- Nothing at all
Short-lived mental clarity is hard to tell from expectation without a placebo.
More contextCase reports, what public figures say, videos and articles, when options run out and the chemistry
Case reports
From journals, regulators and studies of users. One case proves little.
Harm reportednews-reported case - 1 person - 2025
An anti-doping testing body, citing FDA documentation, describes a 2025 report of persistent eye pain after a person used an intranasal Semax product bought online.
Source: BSCG blog, 2026-08
Mixed resulttrial result in rare group - 24 people
A 24-person pilot found a change in resting brain network signal on fMRI versus placebo. Reviewers said this does not show improved cognition.
What experts and influencers say
Paraphrased from the linked sources.
Lists Semax among compounding substances with possible safety risks. Cites possible immune reactions from aggregation and impurities and says it has little or no safety data for the proposed routes.
US Food and Drug AdministrationSourceWarns against
Voted 8-5 with one abstention to recommend Semax for the compounding list, against FDA staff advice. Uses reviewed were cerebral ischemia, migraine and trigeminal neuralgia. The vote is not binding.
FDA Pharmacy Compounding Advisory CommitteeSourceRecommends
Money: Press reports say at least seven members of the rebuilt panel have ties to peptide businesses or clinics
Writes that evidence is stronger for cognitive effects than for mood and does not meet the standard for a treatment recommendation. Says she helps patients who choose it to monitor for problems.
Source: Dr Bliss Lewis site, 2026-04
Bliss LewisInstagramMixed view
Advises drug-tested athletes to avoid Semax. Says the anti-doping rule on non-approved substances may cover it and that mislabeled or contaminated products can trigger positive tests.
Source: BSCG blog, 2026-08
Banned Substances Control GroupSourceWarns against
Reported to have personally used Semax and Selank. Said on a podcast that returning restricted peptides to legal compounding would move buyers to ethical suppliers.
Source: PharmaVoice, 2026-04
Robert F. Kennedy Jr.InstagramRecommendsSays they used it
Its evidence report finds little proof of cognitive benefit in healthy people and none for Alzheimer's disease. It notes the key stroke studies were available only as Russian-language abstracts.
Watch and read
Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.
FDA advisers vote to ease peptide restrictions, despite agency concerns
Will Stone, NPR
Reports an FDA advisory panel's narrow vote to let compounders make gray-market peptides including Semax, despite staff concerns about missing human data.
Shows where Semax stands with US regulators.
FDA advisory panel narrowly rejects compounding of one peptide, backs two others
Lizzy Lawrence and Sarah Todd, STAT reporters
Semax was backed 8-5 for migraine, brain ischemia and facial nerve pain, though FDA staff saw thin evidence and many yes voters had industry ties.
Gives the vote count and the evidence objections.
FDA Panel Clears the Way for 6 Banned Peptides. Here's What They're Claimed to Do
Ed Cara, Gizmodo reporter
Plain summary of the reviewed peptides, describing Semax as a claimed brain-protecting and cognition-boosting drug approved only in some Eastern European countries.
Explains what Semax is claimed to do and where it is approved.
When options run out
Uses people turn to when standard treatment has failed.
Stroke recovery add-on
- Who
- Stroke patients in Russia, where Semax is used in routine practice and sits on the national essential drugs list.
- Evidence
- Two Russian stroke studies reported benefit when added to standard care, including higher blood BDNF levels and better rehabilitation timing in one of 110 patients. Both were available only as Russian-language abstracts. Reviewers say well-conducted published trials are lacking.
Trigeminal neuralgia and migraine
- Who
- People with nerve pain or migraine who seek compounded Semax after other treatment.
- Evidence
- FDA staff judged the evidence too weak to support compounding for these uses. An advisory panel still voted narrowly in favor.
- Route
- US compounding under section 503A, pending an FDA decision
Cognitive dulling after prolonged stress
- Who
- Patients with mood symptoms plus mental slowing who ask psychiatrists about nootropic peptides.
- Evidence
- A psychiatrist who reviewed the literature says the data fall short of a treatment recommendation and long-term and drug-interaction data are missing.
Source: Dr Bliss Lewis site, 2026-04
Legal last-resort routes
Expanded access (compassionate use)
For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.
Right to Try
For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.
Source: FDA, Right to Try
Trial finders
Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.
Source: NIH, finding a clinical trial
Personal import for serious conditions
FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.
Source: FDA, personal importation
Patient-specific compounding
When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.
Amino-acid sequence
Questions people ask
Does Semax improve focus and memory?
No controlled trials in healthy people were found. Users report sharper focus for a few hours, which is hard to tell from expectation without a placebo.
What is Semax approved for?
It is registered in Russia for stroke and other brain conditions. Thirteen Russian stroke studies cover about 1,000 patients, mostly without clear randomization or blinding.
What are the side effects of Semax?
Studies report no significant side effects but do not say how they collected them. Users report irritability or anxiety and nose irritation, and FDA cites the risk of immune reactions and impurities in compounded versions.
Is Semax legal in the US?
FDA advisers voted 8 to 5 in July 2026 to back compounding, but FDA staff opposed it and FDA had not acted by late September 2026.
Your notebook
Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.
Sources
- 2024 review of Semax studies in stroke (Korsakov Journal)
- 2018 Russian meta-analysis of Semax in stroke
- McDermott: July 2026 advisory committee votes
Structure: PubChem